Healthwise
To print: Use your web browser's print feature. Close this window after printing.

Omalizumab for Asthma

Table of Contents


Topic Overview

Omalizumab (Xolair) is a medicine approved by the U.S. Food and Drug Administration (FDA) for use in people age 12 and older who have moderate or severe persistent asthma. This medicine costs a lot more than any of the standard treatments for asthma.

The medicine works by blocking immunoglobulin E (IgE) from attaching to allergens. When IgE attaches to an allergen, it sets off a process that leads to the symptoms of an allergic reaction.

This medicine may help reduce asthma episodes, improve peak expiratory flow (PEF), and reduce the need for other medicines. It may also reduce emergency room visits and hospital stays. But more study is needed.

Omalizumab is given as a shot. The dose depends on your body weight and IgE level.

Your doctor may recommend this medicine if:

Severe allergic reactions, including anaphylaxis, can occur with omalizumab, but this is rare. So people who get this medicine are watched for 2 hours after they get their first 2 doses. They should also carry epinephrine in case they have an allergic reaction after treatment.


References

Other Works Consulted


Credits for Omalizumab for Asthma

Current as of: July 6, 2021

Author: Healthwise Staff
Medical Review:
E. Gregory Thompson MD - Internal Medicine
Adam Husney MD - Family Medicine
Rohit K Katial MD - Allergy and Immunology


Note: The "printer friendly" document will not contain all the information available in the online document. Some information (e.g. cross-references to other topics, definitions or medical illustrations) is only available in the online version.

© 1995-2021 Healthwise, Incorporated. Healthwise, Healthwise for every health decision, and the Healthwise logo are trademarks of Healthwise, Incorporated.
This information does not replace the advice of a doctor. Healthwise, Incorporated disclaims any warranty or liability for your use of this information.